Back to Archived Journals » Current Biomarker Findings » Volume 3

Biomarkers of diffuse large B-cell lymphoma: impact on diagnosis, treatment, and prognosis

Authors Coutinho R, Gribben J

Received 1 October 2012

Accepted for publication 27 November 2012

Published 1 February 2013 Volume 2013:3 Pages 17—34


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 5

Rita Coutinho, John Gribben

Centre for Haemato-Onocology, Barts Cancer Institute, Queen Mary, University of London, London, United Kingdom

Abstract: Introduction of immunochemotherapy as frontline treatment for diffuse large B-cell lymphoma (DLBCL) has significantly increased survival. However, patients refractory to rituximab-containing regimens have a very poor survival. These differences in clinical behavior might lie behind the biological heterogeneity well recognized in this disease. Advanced molecular research has helped us to define DLBCL subgroups which harbor distinct oncogenic events and response to immunochemotherapy. The field of biomarker discovery in DLBCL has become more complex over the last decade and a broad up-to-date review on this topic is lacking. The aim for this review was to offer the hematology community a comprehensive overview of clinical and biological markers which have a diagnostic and prognostic potential and that might be amenable to therapeutic targeting. Some well known markers are reassessed in light of recent findings.

Keywords: DLBCL, immunochemotherapy, rituximab, biomarkers

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]